5 Cheap Large Cap Stocks to Buy Now

2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating. BofA said the update reflects changes made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.

On March 30, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that its applications for a proposed biosimilar to Xolair, oromalizumab, have been accepted for review by both the U.S. FDA and the European Medicines Agency. The filings include a Biologics License Application and a Marketing Authorization Application and cover all approved indications of the reference product, including moderate-to-severe persistent allergic asthma.

On the same day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and biopharmaceutical medicines globally.